- Home
- MGNI vs AMPH Comparison
MGNI vs AMPH Comparison
Compare MGNI & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- AMPH
- Stock Information
- Founded
- MGNI 2007
- AMPH 1996
- Country
- MGNI United States
- AMPH United States
- Employees
- MGNI N/A
- AMPH N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- AMPH Health Care
- Exchange
- MGNI Nasdaq
- AMPH Nasdaq
- Market Cap
- MGNI 2.4B
- AMPH 1.1B
- IPO Year
- MGNI N/A
- AMPH 2014
- Fundamental
- Price
- MGNI $24.22
- AMPH $23.20
- Analyst Decision
- MGNI Strong Buy
- AMPH Hold
- Analyst Count
- MGNI 13
- AMPH 5
- Target Price
- MGNI $20.85
- AMPH $38.00
- AVG Volume (30 Days)
- MGNI 2.8M
- AMPH 502.3K
- Earning Date
- MGNI 08-06-2025
- AMPH 08-06-2025
- Dividend Yield
- MGNI N/A
- AMPH N/A
- EPS Growth
- MGNI N/A
- AMPH N/A
- EPS
- MGNI 0.21
- AMPH 2.77
- Revenue
- MGNI $674,622,000.00
- AMPH $730,659,000.00
- Revenue This Year
- MGNI $0.32
- AMPH $0.67
- Revenue Next Year
- MGNI $11.02
- AMPH $5.18
- P/E Ratio
- MGNI $114.41
- AMPH $8.39
- Revenue Growth
- MGNI 5.59
- AMPH 8.05
- 52 Week Low
- MGNI $8.22
- AMPH $22.64
- 52 Week High
- MGNI $25.27
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- MGNI 88.62
- AMPH 37.06
- Support Level
- MGNI $20.13
- AMPH $22.81
- Resistance Level
- MGNI $24.46
- AMPH $24.52
- Average True Range (ATR)
- MGNI 0.97
- AMPH 0.74
- MACD
- MGNI 0.53
- AMPH -0.22
- Stochastic Oscillator
- MGNI 97.53
- AMPH 11.27
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.